Central retinal thickness μm (CRT) change at 1 year The aim of treatment is to reduce central retinal thickness so thinner is better. · people with neovascular age‐related macular degeneration
1 finding from 1 review
QoL · people with neovascular age‐related macular degeneration
1 finding from 1 review
Cost of treatment per person at 1 year · people with neovascular age‐related macular degeneration
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with endophthalmitis · people with neovascular age‐related macular degeneration
Extended‐fixed showed no clear difference in endophthalmitis (ocular adverse event) compared with monthly injections (low certainty).
1 finding from 1 review
Gain of 3 or more lines of visual acuity · people with neovascular age‐related macular degeneration
As needed may leads to lower gain of ≥ 15 letters visual acuity at 1 year compared with monthly injections (low certainty).
1 finding from 1 review
Central retinal thickness μm (CRT) change at 1 year The aim of treatment is to reduce central retinal thickness so thinner is better. · people with neovascular age‐related macular degeneration
1 finding from 1 review
QoL · people with neovascular age‐related macular degeneration
1 finding from 1 review
Cost of treatment per person at 1 year · people with neovascular age‐related macular degeneration
1 finding from 1 review
Proportion of participants with endophthalmitis · people with neovascular age‐related macular degeneration
As needed probably leads to lower endophthalmitis (ocular adverse event) compared with monthly injections (moderate certainty).
1 finding from 1 review
Change in BCVA at 1 year (ETDRS letters score, the higher the score the better) · people with neovascular age‐related macular degeneration
1 finding from 1 review
Gain of 3 or more lines of visual acuity · people with neovascular age‐related macular degeneration
Extended‐fixed showed no clear difference in gain of ≥ 15 letters visual acuity at 1 year compared with monthly injections (moderate certainty).
1 finding from 1 review
Participant global assessment of success Not measured · adult participants with patellar tendinopathy
1 finding from 1 review
Quality of life · adult participants with patellar tendinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · adult participants with patellar tendinopathy
1 finding from 1 review
Adverse event · adult participants with patellar tendinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tendon rupture · adult participants with patellar tendinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Knee pain (long term) VAS scale: 0 to 10; higher score = worse pain. · adult participants with patellar tendinopathy
1 finding from 1 review
Function · adult participants with patellar tendinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐reported pain · children aged 2‐19 years with mixed medical (acute or chronic illness) or generally healthy undergoing venipuncture, immunization,…
1 finding from 1 review
Observer‐reported distress · children aged 3‐18 years with mixed medical (acute or chronic illness) or generally healthy undergoing immunization, intravenous…
1 finding from 1 review